BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37820087)

  • 1. Promises of oncolytic viral therapy for adult and children with brain glioma.
    Patiño-García A; Alonso MM; Gállego Pérez-Larraya J
    Curr Opin Oncol; 2023 Nov; 35(6):529-535. PubMed ID: 37820087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic viruses as treatment for adult and pediatric high-grade gliomas: On the way to clinical success.
    Hervás-Corpión I; Alonso MM
    Int Rev Cell Mol Biol; 2023; 379():169-188. PubMed ID: 37541723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunovirotherapy for the Treatment of Glioblastoma and Other Malignant Gliomas.
    Estevez-Ordonez D; Chagoya G; Salehani A; Atchley TJ; Laskay NMB; Parr MS; Elsayed GA; Mahavadi AK; Rahm SP; Friedman GK; Markert JM
    Neurosurg Clin N Am; 2021 Apr; 32(2):265-281. PubMed ID: 33781507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Oncolytic virus therapy for malignant brain tumors].
    Ino Y; Todo T
    Brain Nerve; 2009 Jul; 61(7):815-22. PubMed ID: 19618859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Oncolytic viruses for therapy of malignant glioma].
    Sosnovtceva AO; Grinenko NF; Lipatova AV; Chumakov PM; Chekhonin VP
    Biomed Khim; 2016 May; 62(4):376-90. PubMed ID: 27562991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic Virotherapy in Glioma Tumors.
    Rius-Rocabert S; García-Romero N; García A; Ayuso-Sacido A; Nistal-Villan E
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and interim survival data after intracranial administration of M032, a genetically engineered oncolytic HSV-1 expressing IL-12, in pet dogs with sporadic gliomas.
    Omar NB; Bentley RT; Crossman DK; Foote JB; Koehler JW; Markert JM; Platt SR; Rissi DR; Shores A; Sorjonen D; Yanke AB; Gillespie GY; Chambers MR
    Neurosurg Focus; 2021 Feb; 50(2):E5. PubMed ID: 33524948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic virus Ad-TD-nsIL-12 inhibits glioma growth and reprograms the tumor immune microenvironment.
    Li S; Guo Y; Ning W; Chen Y; Xu J; Zhao C; Wang J; Qu Y; Zhang M; Wang P; Wang Y; Wang S; Zhang H
    Life Sci; 2024 Jan; 336():122254. PubMed ID: 37977355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic viral therapy of malignant glioma.
    Parker JN; Bauer DF; Cody JJ; Markert JM
    Neurotherapeutics; 2009 Jul; 6(3):558-69. PubMed ID: 19560745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic virotherapy for the treatment of pediatric brainstem gliomas.
    Gállego Pérez-Larraya J; García-Moure M; Alonso MM
    Rev Neurol (Paris); 2023 Jun; 179(5):475-480. PubMed ID: 37061388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic HSV-1 for the treatment of brain tumours.
    Markert JM; Parker JN; Buchsbaum DJ; Grizzle WE; Gillespie GY; Whitley RJ
    Herpes; 2006 Nov; 13(3):66-71. PubMed ID: 17147910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy.
    Menotti L; Avitabile E
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Current Landscape of Oncolytic Herpes Simplex Viruses as Novel Therapies for Brain Malignancies.
    Bernstock JD; Hoffman SE; Chen JA; Gupta S; Kappel AD; Smith TR; Chiocca EA
    Viruses; 2021 Jun; 13(6):. PubMed ID: 34204248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active immunotherapy: oncolytic virus therapy using HSV-1.
    Todo T
    Adv Exp Med Biol; 2012; 746():178-86. PubMed ID: 22639168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic Viral Therapy for Malignant Glioma and Their Application in Clinical Practice.
    Shoaf ML; Desjardins A
    Neurotherapeutics; 2022 Oct; 19(6):1818-1831. PubMed ID: 35674873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances and potential pitfalls of oncolytic viruses expressing immunomodulatory transgene therapy for malignant gliomas.
    Zhang Q; Liu F
    Cell Death Dis; 2020 Jun; 11(6):485. PubMed ID: 32587256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical advances in oncolytic virotherapy for pediatric brain tumors.
    Ghajar-Rahimi G; Kang KD; Totsch SK; Gary S; Rocco A; Blitz S; Kachurak K; Chambers MR; Li R; Beierle EA; Bag A; Johnston JM; Markert JM; Bernstock JD; Friedman GK
    Pharmacol Ther; 2022 Nov; 239():108193. PubMed ID: 35487285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic immunovirotherapy for high-grade gliomas: A novel and an evolving therapeutic option.
    Asija S; Chatterjee A; Goda JS; Yadav S; Chekuri G; Purwar R
    Front Immunol; 2023; 14():1118246. PubMed ID: 37006286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic virus therapy for malignant gliomas: entering the new era.
    Fudaba H; Wakimoto H
    Expert Opin Biol Ther; 2023 Mar; 23(3):269-282. PubMed ID: 36809883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic Virotherapy for the Treatment of Malignant Glioma.
    Foreman PM; Friedman GK; Cassady KA; Markert JM
    Neurotherapeutics; 2017 Apr; 14(2):333-344. PubMed ID: 28265902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.